5 35 62 Table 5: Comparison of Cyclins and CDKIs Between Phases in the Patient Groups Group Cyclin/CDKI G0/G1-S G0/G1-G2/M S-G2/M A P< 0.
The present study used flow cytometry to analyze the expression of cyclins A, B, D, and E, and CDKIs p21 and p16 in patients with CML and MM, and controls.
This finding suggests another imbalance between cyclins and CDKIs that facilitates malignant cellular proliferation.
The level of expression of p16 did not follow the overexpression of cyclin D during the GO/G1 phase, which was another imbalance between cyclins and CDKIs.
In conclusion, the present findings indicate that synthetic CDKIs may be a promising new treatment for CML and MM.
Conclusion: Elevated cyclin expression during cell cycle phases in the CML and MM patients was not associated with elevated CDKI expression.
Cellular checkpoint integrity is often lost as a result of CDKI inactivation or cyclin overexpression (11).
Recent data show that low or undetectable expression of CDKI genes is a significant marker for the active phase of the disease; therefore, several.
As the number of control cells in the G2/M phase was insufficient, cyclin and CDKI measurements could not be performed in this group.
Except for the G2/M phase, a similar pattern of cyclin and CDKI expression was observed in the controls and MM patients.